What the incretin literature actually covers
GLP-1 receptor agonists entered the literature as glucoregulatory agents and broadened from there. Semaglutide is the most documented single-agonist compound of the group, with a published record spanning glycemic control, gastric emptying and appetite signalling. Retatrutide is the newer triple agonist, engaging GLP-1, GIP and glucagon receptors simultaneously, and the body-composition figures reported in its trial literature are the reason it draws more search interest than any other research peptide in Canada right now. Tirzepatide sits between the two as a dual GLP-1/GIP agonist. Read the primary sources before designing anything: the dose-response curves differ sharply between compounds and between species.





